MedTrace Logo

Effects of Manual Diaphragmatic Technique Versus Lateral Coastal Breathing Exercises Among COPD Patients.

NCT06844994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-02-25

No results posted yet for this study

Summary

Chronic obstructive pulmonary disease is a common, preventable as well treatable disorder, which is also one of the main reasons of high mortality and morbidity characterized by irreversible airflow limitation and has respiratory system involved. The aim of this study is to evaluate the comparative effects of manual diaphragmatic technique and lateral coastal breathing on COPD patients, that these exercises will have beneficial effects or not on COPD patients. Manual diaphragmatic technique and lateral coastal breathing will increase the functional capacity and relieve the symptoms dyspnea, enhance the chest wall expansion.

Conditions

Interventions

OTHER

Manual Diaphragmatic Technique

The intervention will be given 3 days per week for up to 6 weeks starting assessment with modified Borg scale questionnaire will be asked from the patient to evaluate the patient's dyspnea level. The patient at first will be asked to do 5-6 diaphragmatic breathing in upright position and then will be asked to breathe with the breather device after complete inhalation the patient will blow hard in the device. The patient will be asked to inhale and then hold for 2-3 second and breathe out through the device with the 3 sets with each set including 8 repetitions same cycle with relaxed diaphragmatic breathing between each set

OTHER

Lateral Coastal Breathing

The group B will be the lateral coastal breathing that will be given 2 times a day, 3 days per week for up to 6 weeks. The patient will be asked by practitioner to perform 4 to 5 times lateral coastal breathing in suitable sitting or lying position

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Qurat ul Ain, MS · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2024-12-30
Completion
2025-01-15

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06844994 on ClinicalTrials.gov